Unmasking Multiple Sclerosis

Unmasking Multiple Sclerosis

Multiple SCLEROSIS Awareness March is Multiple Sclerosis (MS) Awareness Month, so this WEEKLY takes a look at the science behind the disease and some of the treatments developed for it. MS typically occurs in susceptible individuals between the ages of 20 and 50, and...
Coming Soon? A New Biologic

Coming Soon? A New Biologic

Coming Soon? A New Biologic For the past two decades, monoclonal antibodies (mAbs) have dominated the biologic drugs market. Doctors use these blockbuster products for a range of diseases, including many cancers and autoimmune diseases. In addition to their...
Drugging The Undruggable

Drugging The Undruggable

Antagonists Fight A Good Fight Small molecule inhibitors, also known as antagonists in the industry, fight a good fight. In fact, many drugs on the market today work by inhibiting overactive, disease-associated proteins. Novartis’ (Basel, Switzerland) top...
The Danger Of Antibiotic Resistance

The Danger Of Antibiotic Resistance

THE STATE OF ANTIBIOTICS One of the greatest public health challenges of the twenty first century—drug resistant bacteria—prompted the first ever Antibiotics Summit at the White House earlier this month. Antibiotic resistance occurs when a few bacteria in a given...
Inching Across The Blood-Brain Barrier

Inching Across The Blood-Brain Barrier

A Constant Hurdle in Drug Delivery When it comes to achieving success in drug development, picking the right drug target and developing an effective inhibitor (or activator) is only half the battle. A drug candidate may appear promising in cell-based testing—and even...